MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
BEAM Beam Therapeutics
- 29.010
- +2.160+8.04%
Close Dec 20 16:00 ET
- 29.031
- +0.021+0.07%
Post 20:01 ET
2.40BMarket Cap-18.36P/E (TTM)
29.200High26.735Low2.74MVolume26.900Open26.850Pre Close78.84MTurnover4.00%Turnover RatioLossP/E (Static)82.81MShares49.50052wk High3.04P/B1.99BFloat Cap20.84052wk Low--Dividend TTM68.63MShs Float138.522Historical High--Div YieldTTM9.18%Amplitude13.000Historical Low28.726Avg Price1Lot Size
About Beam Therapeutics Company
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Company Profile
SymbolBEAM
Company NameBeam Therapeutics
Listing DateFeb 6, 2020
Issue Price17.00
Founded2017
CEOMr. John Evans
MarketNASDAQ
Employees436
Fiscal Year Ends12-31
Address238 Main Street,9th floor
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142-1016
Phone1-857-327-8775
Websitehttp://www.beamtx.com
Company Executives
- Name
- Position
- Salary
- John Evans
- Chief Executive Officer, Principal Accounting Officer and Director
- 6.28M
- Dr. Christine Bellon, PhD
- Chief Legal Officer and Secretary
- 2.28M
- Dr. Amy Simon, M.D.
- Chief Medical Officer
- 2.55M
- Sravan K. Emany
- Chief Financial Officer
- --
- Dr. Giuseppe Ciaramella, PhD
- President
- 2.79M
- Chirfi Guindo
- Director
- --
- Kathleen E. Walsh
- Independent Director
- 447.72K
- Graham K. Cooper
- Independent Director
- 450.22K
- Christi Shaw
- Independent Director
- 772.68K
- Dr. Mark C. Fishman, M.D.
- Lead Independent Director
- 465.22K
- Dr. John M. Maraganore,PhD
- Independent Director
- 435.22K
- Dr. Carole Ho, M.D.
- Independent Director
- 442.72K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
